CSPC Anbenitamab Cuts Death Risk 61% in Phase III Gastric Cancer Trial
Anbenitamab reduced the risk of death by 61% in a Phase III trial in advanced HER2-positive gastric cancer.
Anbenitamab reduced the risk of death by 61% in a Phase III trial in advanced HER2-positive gastric cancer.